Atomoxetine for the Treatment of Executive Dysfunction in Parkinson's Disease: A Pilot Open-Label Study

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Movement Disorders (Impact Factor: 5.68). 01/2009; 24(2):277-82. DOI: 10.1002/mds.22307
Source: PubMed


Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P < 05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.

Download full-text


Available from: Kevin Biglan, Mar 10, 2014
  • Source
    • "Verbal memory declines have been documented with both natural (Epperson et al. 2013) and surgical menopause (Sherwin 2005) and may be particularly amenable to improvement if addressed early in the menopause transition. Similarly, a previous study (Epperson et al. 2011) demonstrated that atomoxetine, a non-stimulant medication FDA-approved for the treatment of ADHD (Asherson et al. 2014) and studied with variable success in other disorders (Beglinger et al. 2009; Marsh et al. 2009; Stahl 2003), significantly improved subjective EFs and performance on the verbal paired associates memory task in a similar sample of menopausal women. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women. This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints. Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40-60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest. Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range. LDX 40-60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.
    Psychopharmacology 06/2015; 232(16). DOI:10.1007/s00213-015-3953-7 · 3.88 Impact Factor
  • Source
    • "The randomization groups were matched for age, IQ, education level, disease severity as indexed by the Unified Parkinson's Disease Rating Scale motor subscale (Fahn et al., 1987), total levodopa equivalent daily dose as well as dopamine agonist levodopa equivalent daily dose (Table 1). A dose of 40 mg was used to ensure tolerability based on previous studies (Jankovic, 2009; Marsh et al., 2009; Weintraub et al., 2010b). As peak plasma concentration for atomoxetine is achieved "
    [Show abstract] [Hide abstract]
    ABSTRACT: Noradrenergic dysfunction may play a significant role in cognition in Parkinson's disease due to the early degeneration of the locus coeruleus. Converging evidence from patient and animal studies points to the role of noradrenaline in dopaminergically insensitive aspects of the parkinsonian dysexecutive syndrome, yet the direct effects of noradrenergic enhancement have not to date been addressed. Our aim was to directly investigate these, focusing on impulsivity during response inhibition and decision making. To this end, we administered 40 mg atomoxetine, a selective noradrenaline re-uptake inhibitor to 25 patients with Parkinson's disease (12 female /13 male; 64.4 ± 6.9 years old) in a double blind, randomized, placebo controlled design. Patients completed an extensive battery of neuropsychological tests addressing response inhibition, decision-making, attention, planning and verbal short term memory. Atomoxetine improved stopping accuracy on the Stop Signal Task [F(1,19) = 4.51, P = 0.047] and reduced reflection impulsivity [F(1,9) = 7.86, P = 0.02] and risk taking [F(1,9) = 9.2, P = 0.01] in the context of gambling. The drug also conferred effects on performance as a function of its measured blood plasma concentration: it reduced reflection impulsivity during information sampling [adjusted R(2) = 0.23, F(1,16) = 5.83, P = 0.03] and improved problem solving on the One Touch Stockings of Cambridge [adjusted R(2) = 0.29, F(1,17) = 8.34, P = 0.01]. It also enhanced target sensitivity during sustained attention [F(1,9) = 5.33, P = 0.046]. The results of this exploratory study represent the basis of specific predictions in future investigations on the effects of atomoxetine in Parkinson's disease and support the hypothesis that targeting noradrenergic dysfunction may represent a new parallel avenue of therapy in some of the cognitive and behavioural deficits seen in the disorder.
    Brain 06/2014; DOI:10.1093/brain/awu117 · 9.20 Impact Factor
  • Source
    • "Hence, our findings add further support to the notion that executive deficits in higher order control of actions like internal movement selection and choice processes in Parkinson's disease may be related to neurotransmitter system dysfunction beyond the dopaminergic system, such as, e.g. acetylcholine, noradrenaline or serotonin (Marsh et al., 2009; Schmitt et al., 2010; Narayanan et al., 2013; Ye et al., 2014a, b). "

    Clinical Neurophysiology 06/2014; 125:S129. DOI:10.1016/S1388-2457(14)50421-X · 3.10 Impact Factor
Show more